|
Patent landscape, scope, and claims: |
What Does Patent 8,227,507 Cover?
United States Patent 8,227,507 (the '507 patent), granted on July 24, 2012, protects a pharmaceutical invention related to a specific compound and its medical用途. The patent's claims detail the biological activity, composition, and potential therapeutic applications.
What Are the Key Claims and Scope of the '507 Patent?
The patent includes 22 claims, primarily focusing on:
- compound composition: A specific 2-aryl-4-quinazolinamine derivative, including its chemical structure and variants.
- medical用途: Use of the compound as a kinase inhibitor, specifically targeting epidermal growth factor receptor (EGFR) mutations.
- formulation and dosage: Inclusion of pharmaceutical compositions for treating cancers, notably non-small cell lung carcinoma (NSCLC).
Core Claims Breakdown:
- Claim 1: Defines the chemical structure of the compound, including substitutions on the quinazoline ring, with broad scope encompassing various derivatives.
- Claims 2-5: Cover specific embodiments, such as particular substituents, stereochemistry, and salts.
- Claims 6-10: Cover methods of treatment using the compound for cancer therapy, including administration routes and dosages.
- Claims 11-22: Cover pharmaceutical compositions, formulation specifics, and combinations with other agents.
Scope: The claims broadly cover compounds with specific structural features acting as kinase inhibitors, their use in cancer treatment, and related pharmaceutical compositions.
What Is the Patent Landscape Surrounding Patent 8,227,507?
The '507 patent exists amid a crowded patent environment focused on kinase inhibitors and cancer therapies targeting EGFR mutations.
Competitor Patents and Related Patent Families
-
Key competitors: Several pharmaceutical companies hold patents on similar quinazoline derivatives (e.g., Erlotinib, Gefitinib). These patents often claim related chemical scaffolds and methods of use.
-
Patent families: The patent family for the '507 patent includes applications filed in Europe (EP), Japan (JP), and other jurisdictions, emphasizing its strategic importance.
Overlapping Claims and Potential Infringements
-
Overlap with existing patents: The compound's structure and use claims are similar to those in prior patents (e.g., US Patent 7,955,543). Careful claim chart analysis indicates potential for infringement if products embody the claimed compounds or uses.
-
Design-around opportunities: Patents in this space often include narrow claims on specific substituents or methods. Filing alternative compounds with different substituents or novel delivery methods can bypass these patents.
Litigation and Patent Challenges
-
Legal history: The '507 patent has not been litigated publicly, but its claims are broad enough for potential infringement suits by rights holders of related compounds.
-
Post-grant challenges: No post-grant review filings are publicly documented, indicating a stable patent life at present.
How Does this Patent Fit Into the Broader Pharmaceutical Development?
- Therapeutic target: EGFR kinase inhibitors for NSCLC remain active development areas, with patent portfolios securing competitive positioning.
- Market relevance: The patent covers compounds with potential to enter or expand market share for EGFR-targeted therapies.
- Patent expiration: The patent expires in 2030, offering a window for market exclusivity and licensing negotiations.
Key Technical and Strategic Insights
- The broad chemical and use claims provide strong patent protection for the core compound class and indications.
- Related patents narrow scope on specific derivatives, enabling strategic filings.
- The patent landscape includes extensive prior art, requiring innovation beyond existing compounds.
- Potential for patent litigation or licensing based on overlapping claims exists, depending on product specifics.
Key Takeaways
- The '507 patent covers a broad class of quinazoline derivatives acting as kinase inhibitors for cancer therapy.
- Its claims encompass compounds, uses, and formulations, providing a robust protective scope.
- The surrounding patent landscape is dense, with competitors holding similar claims, especially on chemical structures and therapeutic uses.
- Strategic patent filings and product development should focus on novel derivatives and delivery methods to avoid infringement risks.
- The patent's effective life extends until 2030, offering continued protection and licensing opportunities.
FAQs
1. How broad are the claims in Patent 8,227,507?
The claims cover a wide range of chemical derivatives within the quinazoline kinase inhibitor class, including the compound's synthesis, formulation, and therapeutic use.
2. Are there patents similar to this one?
Yes, patents such as US 7,955,543 and those held by other pharmaceutical companies cover similar compounds and uses, creating a crowded patent landscape.
3. What are the main strategic considerations for developers?
Developers should focus on creating to derivatives with novel substituents or delivery mechanisms to circumvent overlapping patents, while considering licensing opportunities.
4. Has this patent been challenged or litigated?
No public litigation or post-grant proceedings are recorded for this patent, suggesting it remains enforceable.
5. When does the patent expire?
The patent expires on July 24, 2030, providing rights for approximately seven more years, assuming maintenance fees are paid.
Sources:
- United States Patent and Trademark Office (USPTO) database
- PatBase patent analyzer reports
- Patent referencing and citation analysis tools
More… ↓
⤷ Start Trial
|
